This three-part series updates the Society of Family Planning’s 2012 Cancer and contraception clinical guidance. Part 1 addresses key considerations for clinical care.  Part 2 provides actionable, clinical recommendations for breast, ovarian, uterine, and cervical cancer, and Part 3 provides actionable, clinical recommendations for skin, blood, gastrointestinal, liver, lung, central nervous system, and other cancers.

This document serves as a revision to the Society of Family Planning’s 2010 guidelines, integrating literature on new techniques and research and addressing the clinical, medical, and sociolegal questions surrounding the induction of fetal asystole. Insufficient evidence exists to recommend routine induction of fetal asystole before previable medication and procedural abortion. However, at periviable gestations ... Read more >

The objective of this Clinical Recommendation is to review relevant literature and provide evidence-based recommendations for medication abortion between 14 0/7 and 27 6/7 weeks of gestation, with a focus on mifepristone-misoprostol and misoprostol-only regimens. We systematically reviewed PubMed articles published between 2008 and 2022 and reviewed reference lists of included articles to identify additional ... Read more >

Pain is a complex phenomenon that involves more than a simple physical response to external stimuli. In maternal-fetal surgical procedures, fetal analgesia is used primarily to blunt fetal autonomic responses and minimize fetal movement. The purpose of this Consult is to review the literature on what is known about the potential for fetal awareness of ... Read more >

This document is currently under revision. Clinical guidance is rigorously developed to reflect the best available evidence at the time of publication. It is designed as a resource to assist clinicians in providing family planning care. It is not intended to substitute for the independent professional judgment of the treating clinician. We recognize that continued ... Read more >